What is Precigen, Inc. (PGEN) stock price today?

Precigen, Inc. (PGEN) is currently trading at $7.60, up 0.8% today.

What is PGEN P/E ratio?

Precigen, Inc.'s P/E ratio is -7.55. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is PGEN return on equity (ROE)?

Precigen, Inc.'s return on equity (ROE) is -498.32%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Precigen, Inc.'s market cap?

Precigen, Inc. has a market capitalization of $2.71B.

NASDAQ · Biotechnology

Precigen, Inc. (PGEN) Stock

$7.60 +0.80% NASDAQ: PGEN Healthcare

Valuation

Metric	Value
Price	$7.60
Market Cap	$2.71B
P/E Ratio	-7.55
P/B Ratio	69.94
P/S Ratio	35.52
EPS (TTM)	$-1.41
52-Week High	$8.98
52-Week Low	$2.99
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-498.32%
ROA	-92.61%
ROCE	-28.02%
Gross Margin	-1060.00%
Operating Margin	-1070.00%
Net Margin	-183.98%
Debt/Equity	2.26
Current Ratio	3.11

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$14.0M	$27.0M	$6.0M	$4.0M	$10.0M
Operating Profit	$-92.0M	$-76.0M	$-100.0M	$-135.0M	$-107.0M
Net Profit	$-92.0M	$28.0M	$-96.0M	$-126.0M	$-251.0M
EPS	$-0.47	$-0.40	$-0.39	$-0.47	$-1.41
Op Margin	-644.5%	-281.4%	-1602.5%	-3440.2%	-1100.8%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$360.0M	$216.0M	$151.0M	$145.0M	$157.0M
Total Liabilities	$253.0M	$90.0M	$33.0M	$107.0M	$136.0M
Cash	$36.0M	$5.0M	$8.0M	$30.0M	$30.0M
Borrowings	$190.0M	$51.0M	$7.0M	$6.0M	$98.0M

Latest News

What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors? Motley Fool · Jul 15, 2026 Precigen Insider Sold Shares Worth $1,113,143, According to a Recent SEC Filing MT Newswires · Jul 2, 2026 Precigen Insider Sold Shares Worth $2,042,864, According to a Recent SEC Filing MT Newswires · Jul 2, 2026 Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason Insider Monkey · Jun 23, 2026 Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS Insider Monkey · Jun 20, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-56.0M	$-65.0M	$-67.0M	$-68.0M	$-88.0M
Investing Cash Flow	$-82.0M	$221.0M	$-5.0M	$-29.0M	$-4.0M
Financing Cash Flow	$1.0M	$0	$0	$0	$-3.0M
Net Cash Flow	$-9.0M	$5.0M	$-41.0M	$22.0M	$1.0M
Free Cash Flow	$-63.0M	$-70.0M	$-68.0M	$-77.0M	$-90.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.03
EV / EBITDA	-21.57
FCF Yield	-3.80%
Quick Ratio	3.89
Interest Coverage	-4.06
Return 1Y	229.22%
Return 3Y	333.73%
Return 5Y	1.02%

Ownership

Insiders Held13.71%

Institutions Held71.19%

Institutions Float Held82.50%

Institutional Holder	Shares	Report Date
Patient Capital Management, LLC	17,817,387	2026-03-31
Blackrock Inc.	15,223,191	2026-03-31
State Street Corporation	10,890,124	2026-03-31
Vanguard Capital Management LLC	7,148,996	2026-03-31
Diametric Capital, Lp	6,801,788	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ABEOAbeona Therapeutics Inc.	$4.96	-2.36%	-4.43	$282.70M	0.00%
CRSPCRISPR Therapeutics AG	$50.44	-3.65%	-11.62	$4.86B	0.00%
DTILPrecision BioSciences, Inc.	$6.43	+2.88%	-2.26	$177.48M	0.00%
EDITEditas Medicine, Inc.	$2.84	+3.27%	-3.50	$435.83M	0.00%
GNPXGenprex, Inc.	$2.75	+4.96%	-0.02	$1.39M	0.00%

About Precigen, Inc.

Precigen, Inc. is led by CEO Helen Sabzevari, employs 143 people, headquartered in US, publicly traded since 2013.

Precigen, Inc. (PGEN) stock trades at $7.60 with a market capitalization of $2.71B. The stock is valued at a price-to-earnings (P/E) ratio of -7.55, price-to-book of 69.94, price-to-sales of 35.52. Over the past 52 weeks the stock has ranged between $2.99 and $8.98, and currently trades 15.4% below its 52-week high.

On profitability, Precigen, Inc. generates a return on equity (ROE) of -498.32%, return on capital employed of -28.02%, an operating margin of -1070.00%, a net profit margin of -183.98%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides